Acute kidney injury risk associated with piperacillin/tazobactam compared with cefepime during vancomycin therapy in hospitalised patients: a cohort study stratified by baseline kidney function

Highlights • Risk of AKI with vancomycin + piperacillin/tazobactam (VPT) versus vancomycin + cefepime (VC) was compared. • Elevated risk of AKI in hospitalised patients receiving VPT was compared with VC. • Association was true in patients with normal renal function but not in those with pre-existin...

Full description

Saved in:
Bibliographic Details
Published in:International journal of antimicrobial agents 2017-07, Vol.50 (1), p.63-67
Main Authors: Jeon, Nakyung, Staley, Ben, Klinker, Kenneth P, Hincapie Castillo, Juan, Winterstein, Almut G
Format: Article
Language:English
Subjects:
Acute kidney injury
Acute Kidney Injury - chemically induced
Adolescent
Adult
Aged
Aged, 80 and over
Anti-Bacterial Agents - adverse effects
beta-Lactamase Inhibitors - adverse effects
Cephalosporins - adverse effects
Drug Therapy, Combination - adverse effects
Female
Humans
Infectious Disease
Inverse probability of treatment weighting
IPTW
Male
Middle Aged
Penicillanic Acid - adverse effects
Penicillanic Acid - analogs & derivatives
Piperacillin - adverse effects
Piperacillin/tazobactam
Renal impairment
Retrospective Studies
Risk Assessment
Vancomycin
Vancomycin - adverse effects
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Risk of AKI with vancomycin + piperacillin/tazobactam (VPT) versus vancomycin + cefepime (VC) was compared. • Elevated risk of AKI in hospitalised patients receiving VPT was compared with VC. • Association was true in patients with normal renal function but not in those with pre-existing renal impairment. • Future studies evaluating drug-associated AKI should consider stratification by baseline renal function.
ISSN:0924-8579
1872-7913
DOI:10.1016/j.ijantimicag.2017.02.023